Mersana Therapeutics (MRSN) Misses Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq rise in choppy trading as tech steadies, Micron results in focus
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Mersana (MRSN) PT Raised to $15 at Citi, Opens Catalyst Watch
May 10, 2023 3:24 PM EDTCiti analyst Ashiq Mubarack raised the price target on Mersana (NASDAQ: MRSN) to $15.00 (from $12.00) while maintaining a Buy rating.
The analys topens a 90-day upside catalyst watch commenting "In mid-2023, MRSN will share topline results from the pivotal UPLIFT Ph2 trial evaluating UpRi in... More
